Daniel Weintraub spends much of his time researching Psychiatry, Parkinson's disease, Disease, Internal medicine and Dementia. His Psychiatry research includes elements of Clinical psychology and Punding. His studies in Parkinson's disease integrate themes in fields like Apathy, Severity of illness, Central nervous system disease and Cohort study.
He combines subjects such as Psychological intervention, Epidemiology and Intensive care medicine with his study of Disease. The concepts of his Internal medicine study are interwoven with issues in Geriatric Depression Scale, Placebo and Effects of sleep deprivation on cognitive performance. His Dementia study integrates concerns from other disciplines, such as Biomarker, Alzheimer's disease, Cognition and Oncology.
The scientist’s investigation covers issues in Parkinson's disease, Psychiatry, Disease, Internal medicine and Dementia. His studies deal with areas such as Rating scale, Clinical psychology, Biomarker, Physical therapy and Movement disorders as well as Parkinson's disease. His Psychiatry course of study focuses on Impulse control disorder and Punding and Dopamine dysregulation syndrome.
His Disease research is multidisciplinary, relying on both Psychological intervention, Neurology and Clinical trial. His research in Internal medicine tackles topics such as Placebo which are related to areas like Randomized controlled trial and Citalopram. His work deals with themes such as Alzheimer's disease and Cognition, Effects of sleep deprivation on cognitive performance, which intersect with Dementia.
His primary areas of study are Parkinson's disease, Disease, Internal medicine, Cognition and Dementia. His research integrates issues of Physical medicine and rehabilitation, Rating scale, Anxiety, Movement disorders and Depression in his study of Parkinson's disease. The study incorporates disciplines such as Psychiatry, Psychosis, Biomarker, Pediatrics and Cohort in addition to Disease.
His Internal medicine study incorporates themes from Gastroenterology and Oncology. His Cognition research includes themes of Cognitive psychology, Behavioral neurology and Cognitive decline. Daniel Weintraub has researched Dementia in several fields, including Neuropsychology, Gerontology and Audiology.
Daniel Weintraub focuses on Parkinson's disease, Disease, Internal medicine, Dementia and Cognition. The various areas that Daniel Weintraub examines in his Parkinson's disease study include Scale, Movement disorders, Physical medicine and rehabilitation and Audiology. His study on Disease also encompasses disciplines like
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Oncology. His Dementia study combines topics in areas such as Cognitive diagnosis and Disease management. He has included themes like Observational study, Anticholinergic, Hypnotic, Antidepressant and Pediatrics in his Cognition study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines
Irene Litvan;Jennifer G. Goldman;Alexander I. Tröster;Ben A. Schmand.
Movement Disorders (2012)
Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Daniel Weintraub;Juergen Koester;Marc N. Potenza;Andrew D. Siderowf.
JAMA Neurology (2010)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider;Pierre N. Tariot;Karen S. Dagerman;Sonia M. Davis.
The New England Journal of Medicine (2006)
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
S. Hoops;S. Nazem;A. D. Siderowf;J. E. Duda.
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.
D. Aarsland;K. Bronnick;C. Williams-Gray;D. Weintraub.
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Daniel Weintraub;Andrew D. Siderowf;Marc N. Potenza;Joseph Goveas.
JAMA Neurology (2006)
MDS Task Force on Mild Cognitive Impairment in Parkinson’s disease: Critical Review of PD-MCI
Irene Litvan;Dag Aarsland;Charles H. Adler;Jennifer G. Goldman.
Movement Disorders (2011)
Depression Rating Scales in Parkinson’s Disease: Critique and Recommendations
Anette Schrag;Paolo Barone;Richard G. Brown;Albert F.G. Leentjens.
Movement Disorders (2007)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Paolo Barone;Werner Poewe;Stefan Albrecht;Catherine Debieuvre.
Lancet Neurology (2010)
Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease
Daniel Weintraub;Paul J. Moberg;John E. Duda;Ira R. Katz.
Journal of the American Geriatrics Society (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: